{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T21:39:10Z","timestamp":1766180350358},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,7,28]],"date-time":"2010-07-28T00:00:00Z","timestamp":1280275200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1007\/s00417-010-1452-4","type":"journal-article","created":{"date-parts":[[2010,7,27]],"date-time":"2010-07-27T10:24:56Z","timestamp":1280226296000},"page":"15-27","source":"Crossref","is-referenced-by-count":35,"title":["Meta-analysis and review on the effect of bevacizumab in diabetic macular edema"],"prefix":"10.1007","volume":"249","author":[{"given":"Sunali","family":"Goyal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"LaValley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manju L.","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,7,28]]},"reference":[{"key":"1452_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0161-6420(84)34337-8","volume":"91","author":"R Klein","year":"1984","unstructured":"Klein R, Klein BE, Moss SE (1984) Visual impairment in diabetes. Ophthalmology 91:1\u20139","journal-title":"Ophthalmology"},{"key":"1452_CR2","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S0161-6420(94)31217-6","volume":"101","author":"SE Moss","year":"1994","unstructured":"Moss SE, Klein R, Klein BE (1994) Ten-year incidence of visual loss in a diabetic population. Ophthalmology 101:1061\u20131070","journal-title":"Ophthalmology"},{"key":"1452_CR3","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0161-6420(86)33650-9","volume":"93","author":"GH Bresnick","year":"1986","unstructured":"Bresnick GH (1986) Diabetic macular edema. A review. Ophthalmology 93:989\u2013997","journal-title":"Ophthalmology"},{"key":"1452_CR4","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/archopht.1984.01040030405011","volume":"102","author":"R Klein","year":"1984","unstructured":"Klein R, Klein BE, Moss SE, Davis MD, DeMets DL (1984) The Wisconsin epidemiologic study of diabetic retinopathy: III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 102:527\u2013532","journal-title":"Arch Ophthalmol"},{"key":"1452_CR5","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/S0161-6420(84)34102-1","volume":"91","author":"R Klein","year":"1984","unstructured":"Klein R, Klein BE, Moss SE, Davis MD, DeMets DL (1984) The Wisconsin epidemiologic study of diabetic retinopathy: IV. Diabetic macular edema. Ophthalmology 91:1464\u20131474","journal-title":"Ophthalmology"},{"key":"1452_CR6","first-page":"223","volume":"14","author":"RJ Antcliff","year":"1999","unstructured":"Antcliff RJ, Marshall J (1999) The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 14:223\u201332","journal-title":"SemiOphthalmol"},{"key":"1452_CR7","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1056-8727(03)00038-2","volume":"18","author":"PR Aroca","year":"2004","unstructured":"Aroca PR, Salvat M, Fern\u00e1ndez J, M\u00e9ndez I (2004) Risk factors for diffuse and focal macular edema. J Diabetes Complications 18:211\u2013215","journal-title":"J Diabetes Complications"},{"key":"1452_CR8","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1001\/archopht.1985.01050120030015","volume":"103","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1985","unstructured":"Early Treatment Diabetic Retinopathy Study Research Group (1985) Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report no 1. Arch Ophthalmol 103:1796\u20131806","journal-title":"Arch Ophthalmol"},{"key":"1452_CR9","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0161-6420(88)33004-6","volume":"95","author":"FP Nasrallah","year":"1988","unstructured":"Nasrallah FP, Jalkh AE, Van Coppenolle F, Kado M, Trempe CL, McMeel JW, Schepens CL (1988) The role of the vitreous in diabetic macular edema. Ophthalmol 95:1335\u20131339","journal-title":"Ophthalmol"},{"key":"1452_CR10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/archopht.121.1.57","volume":"121","author":"JB Jonas","year":"2003","unstructured":"Jonas JB, Kreissig I, Sofker A, Degenring RF (2003) Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 121:57\u201361","journal-title":"Arch Ophthalmol"},{"key":"1452_CR11","first-page":"426","volume":"8","author":"A Loewenstein","year":"2006","unstructured":"Loewenstein A, Goldstein M (2006) Intravitreal triamcinolone acetonide for diabetic macula edema. Isr Med Assoc J 8:426\u2013427","journal-title":"Isr Med Assoc J"},{"key":"1452_CR12","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1517\/13543784.13.10.1275","volume":"13","author":"MB Grant","year":"2004","unstructured":"Grant MB, Afzal A, Spoerri P, Pan H, Shaw LC, Mames RN (2004) The role of growth factors in the pathogenesis of diabetic retinopathy. Expert Opin Investig Drugs 13:1275\u20131293","journal-title":"Expert Opin Investig Drugs"},{"key":"1452_CR13","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","volume":"331","author":"LP Aiello","year":"1994","unstructured":"Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480\u20131487","journal-title":"N Engl J Med"},{"key":"1452_CR14","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0002-9394(02)01323-5","volume":"133","author":"H Funatsu","year":"2002","unstructured":"Funatsu H, Yamashita H, Ikeda T, Nakanishi Y, Kitano S, Hori S (2002) Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am J Ophthalmol 133:537\u2013543","journal-title":"Am J Ophthalmol"},{"key":"1452_CR15","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.ophtha.2005.06.007","volume":"112","author":"ET Cunningham Jr","year":"2005","unstructured":"Cunningham ET Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ, Goldbaum M, Guyer DR, Katz B, Patel M, Schwartz SD, Macugen Diabetic Retinopathy Study Group (2005) A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmol 112:1747\u20131757","journal-title":"Ophthalmol"},{"key":"1452_CR16","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.ophtha.2006.04.033","volume":"113","author":"DW Chun","year":"2006","unstructured":"Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM (2006) A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmol 113:1706\u20131712","journal-title":"Ophthalmol"},{"key":"1452_CR17","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11864-005-0044-8","volume":"6","author":"J Whisenant","year":"2005","unstructured":"Whisenant J, Bergsland E (2005) Anti-angiogenic strategies in gastrointestinal malignancies. Curr Treat Options Oncol 6:411\u2013421","journal-title":"Curr Treat Options Oncol"},{"key":"1452_CR18","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ajo.2006.05.061","volume":"142","author":"PK Kaiser","year":"2006","unstructured":"Kaiser PK (2006) Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. Am J Ophthalmol 142:660\u2013668","journal-title":"Am J Ophthalmol"},{"key":"1452_CR19","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1345\/aph.1H316","volume":"41","author":"SS Lynch","year":"2007","unstructured":"Lynch SS, Cheng CM (2007) Bevacizumab for neovascular ocular diseases. Ann Pharmacother 41:614\u2013625","journal-title":"Ann Pharmacother"},{"key":"1452_CR20","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/bjo.2006.099598","volume":"90","author":"AE Fung","year":"2006","unstructured":"Fung AE, Rosenfeld PJ, Reichel E (2006) The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 90:1344\u20131349","journal-title":"Br J Ophthalmol"},{"key":"1452_CR21","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/IAE.0b013e31815ec261","volume":"27","author":"M Soheilian","year":"2007","unstructured":"Soheilian M, Ramezani A, Bijanzadeh B, Yaseri M, Ahmadieh H, Dehghan MH, Azarmina M, Moradian S, Tabatabaei H, Peyman GA (2007) Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina 27:1187\u20131195","journal-title":"Retina"},{"key":"1452_CR22","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.ophtha.2007.05.062","volume":"114","author":"Diabetic Retinopathy Clinical Research Network","year":"2007","unstructured":"Diabetic Retinopathy Clinical Research Network (2007) A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 114:1860\u20131867","journal-title":"Ophthalmology"},{"key":"1452_CR23","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00417-007-0688-0","volume":"246","author":"H Ahmadieh","year":"2008","unstructured":"Ahmadieh H, Ramezani A, Shoeibi N, Bijanzadeh B, Tabatabaei A, Azarmina M, Soheilian M, Keshavarzi G, Mohebbi MR (2008) Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 246:483\u2013489","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1452_CR24","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1177\/112067210801800614","volume":"18","author":"H Faghihi","year":"2008","unstructured":"Faghihi H, Roohipoor R, Mohammadi SF, Hojat-Jalali K, Mirshahi A, Lashay A, Piri N, Faghihi Sh (2008) Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema. Eur J Ophthalmol 18:941\u2013948","journal-title":"Eur J Ophthalmol"},{"key":"1452_CR25","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.ophtha.2009.01.011","volume":"116","author":"M Soheilian","year":"2009","unstructured":"Soheilian M, Ramezani A, Obudi A, Bijanzadeh B, Salehipour M, Yaseri M, Ahmadieh H, Dehghan MH, Azarmina M, Moradian S, Peyman GA (2009) Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 116:1142\u20131150","journal-title":"Ophthalmology"},{"key":"1452_CR26","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1136\/bjo.2007.129122","volume":"92","author":"L Paccola","year":"2008","unstructured":"Paccola L, Costa RA, Folgosa MS, Barbosa JC, Scott IU, Jorge R (2008) Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br J Ophthalmol 92:76\u201380","journal-title":"Br J Ophthalmol"},{"key":"1452_CR27","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/IAE.0b013e31819a2d61","volume":"29","author":"DS Lam","year":"2009","unstructured":"Lam DS, Lai TY, Lee VY, Chan CK, Liu DT, Mohamed S, Li CL (2009) Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial. Retina 29:292\u2013299","journal-title":"Retina"},{"key":"1452_CR28","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/01.iae.0000247165.38655.bf","volume":"26","author":"C Haritoglou","year":"2006","unstructured":"Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, Gandorfer A, Ulbig M, Kampik A (2006) Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 26:999\u20131005","journal-title":"Retina"},{"key":"1452_CR29","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.ophtha.2006.12.028","volume":"114","author":"JF Arevalo","year":"2007","unstructured":"Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, Pan-American Collaborative Retina Study Group (2007) Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 114:743\u2013750","journal-title":"Ophthalmology"},{"key":"1452_CR30","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ajo.2007.02.048","volume":"144","author":"A Yanyali","year":"2007","unstructured":"Yanyali A, Aytug B, Horozoglu F, Nohutcu AF (2007) Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am J Ophthalmol 144:124\u2013126","journal-title":"Am J Ophthalmol"},{"key":"1452_CR31","doi-asserted-by":"crossref","first-page":"451","DOI":"10.4103\/0301-4738.36481","volume":"55","author":"A Kumar","year":"2007","unstructured":"Kumar A, Sinha S (2007) Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population. Indian J Ophthalmol 55:451\u2013455","journal-title":"Indian J Ophthalmol"},{"key":"1452_CR32","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1089\/jop.2007.0128","volume":"24","author":"K Ornek","year":"2008","unstructured":"Ornek K, Ornek N (2008) Intravitreal bevacizumab treatment for refractory diabetic macular edema. J Ocul Pharmacol Ther 24:403\u2013407","journal-title":"J Ocul Pharmacol Ther"},{"key":"1452_CR33","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1097\/IAE.0b013e318176de48","volume":"28","author":"D Kook","year":"2008","unstructured":"Kook D, Wolf A, Kreutzer T, Neubauer A, Strauss R, Ulbig M, Kampik A, Haritoglou C (2008) Long-term effect of intravitreal bevacizumab (avastin) inpatients with chronic diffuse diabetic macular edema. Retina 28:1053\u20131060","journal-title":"Retina"},{"key":"1452_CR34","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1097\/IAE.0b013e3181853d2a","volume":"28","author":"MI Roh","year":"2008","unstructured":"Roh MI, Byeon SH, Kwon OW (2008) Repeated intravitreal injection of bevacizumab for clinically significant diabetic macular edema. Retina 28:1314\u20131318","journal-title":"Retina"},{"key":"1452_CR35","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1755-3768.2008.01254.x","volume":"86","author":"X Fang","year":"2008","unstructured":"Fang X, Sakaguchi H, Gomi F, Oshima Y, Sawa M, Tsujikawa M, Ikuno Y, Kamei M, Kusaka S, Tano Y (2008) Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema. Acta Ophthalmol 86:800\u2013805","journal-title":"Acta Ophthalmol"},{"key":"1452_CR36","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1600-0420.2007.01057.x","volume":"86","author":"W Soliman","year":"2008","unstructured":"Soliman W, Vinten M, Sander B, Soliman KA, Yehya S, Rahman MS, Larsen M (2008) Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema. Acta Ophthalmol 86:365\u2013371","journal-title":"Acta Ophthalmol"},{"key":"1452_CR37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3341\/kjo.2009.23.1.17","volume":"23","author":"JW Seo","year":"2009","unstructured":"Seo JW, Park IW (2009) Intravitreal bevacizumab for treatment of diabetic macular edema. Korean J Ophthalmol 23:17\u201322","journal-title":"Korean J Ophthalmol"},{"key":"1452_CR38","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/IAE.0b013e318186c64e","volume":"29","author":"R Velez-Montoya","year":"2009","unstructured":"Velez-Montoya R, Fromow-Guerra J, Burgos O, Landers MB 3rd, Morales-Cat\u00f3n V, Quiroz-Mercado H (2009) The effect of unilateral intravitreal bevacizumab (avastin), in the treatment of diffuse bilateral diabetic macular edema: a pilot study. Retina 29:20\u201326","journal-title":"Retina"},{"key":"1452_CR39","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00417-008-1034-x","volume":"247","author":"JF Arevalo","year":"2009","unstructured":"Arevalo JF, Sanchez JG, Fromow-Guerra J, Pan-American Collaborative Retina Study Group (2009) Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up. Graefes Arch Clin Exp Ophthalmol 247:735\u201343","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1452_CR40","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.ajo.2009.01.009","volume":"147","author":"M Bonini-Filho","year":"2009","unstructured":"Bonini-Filho M, Costa RA, Calucci D, Jorge R, Melo LA Jr, Scott IU (2009) Intravitreal bevacizumab for diabetic macular edema associated with severe capillary loss: one-year results of a pilot study. Am J Ophthalmol 147:1022\u20131030","journal-title":"Am J Ophthalmol"},{"key":"1452_CR41","first-page":"31","volume-title":"Methods for Meta-Analysis in Medical Research","author":"AJ Sutton","year":"2000","unstructured":"Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F (2000) Methods for Meta-Analysis in Medical Research. John Wiley & Sons, New York, pp 31\u201333"},{"key":"1452_CR42","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S0895-4356(98)00131-0","volume":"51","author":"AP Verhagen","year":"1998","unstructured":"Verhagen AP, de Vet HC, de Bie RA, Kessels AG, Boers M, Bouter LM, Knipschild PG (1998) The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 51:1235\u20131241","journal-title":"J Clin Epidemiol"},{"key":"1452_CR43","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analysis. BMJ 327:557\u2013560","journal-title":"BMJ"},{"key":"1452_CR44","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/(SICI)1097-0258(19990215)18:3<321::AID-SIM28>3.0.CO;2-P","volume":"18","author":"S-L Normand","year":"1999","unstructured":"Normand S-L (1999) Tutorial in biostatistics: meta-analysis: formulating, evaluating, combining and reporting. Stat Med 18:321\u2013359","journal-title":"Stat Med"},{"key":"1452_CR45","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","volume":"114","author":"SJ Bakri","year":"2007","unstructured":"Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ (2007) Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114:855\u2013859","journal-title":"Ophthalmology"},{"key":"1452_CR46","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/08820530701543024","volume":"22","author":"RM Dafer","year":"2007","unstructured":"Dafer RM, Schneck M, Friberg TR, Jay WM (2007) Intravitreal ranibizumab and bevacizumab: a review of risk. Semin Ophthalmol 22:201\u2013204","journal-title":"Semin Ophthalmol"},{"key":"1452_CR47","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1136\/bjo.2006.098426","volume":"90","author":"RB Bhisitkul","year":"2006","unstructured":"Bhisitkul RB (2006) Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol 90:1542\u20131547","journal-title":"Br J Ophthalmol"},{"key":"1452_CR48","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1001\/archopht.124.10.1478","volume":"124","author":"MC Gillies","year":"2006","unstructured":"Gillies MC (2006) What we don't know about avastin might hurt us. Arch Ophthalmol 124:1478\u20131479","journal-title":"Arch Ophthalmol"},{"key":"1452_CR49","doi-asserted-by":"crossref","first-page":"5880","DOI":"10.1167\/iovs.08-3078","volume":"50","author":"FC Schlichtenbrede","year":"2009","unstructured":"Schlichtenbrede FC, Mittmann W, Rensch F, Vom Hagen F, Jonas JB, Euler T (2009) Toxicity assessment of intravitreal triamcinolone and bevacizumab in an retinal explant mouse model using two-photon microscopy. Invest Ophthalmol Vis Sci 50:5880\u20135887","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1452_CR50","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00417-007-0660-z","volume":"246","author":"L Wu","year":"2008","unstructured":"Wu L, Mart\u00ednez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME, Maia M, Roca JA, Rodriguez FJ, Pan American Collaborative Retina Group (PACORES) (2008) Twelve-month safety of intravitreal injections of bevacizumab(Avastin): results of the Pan-American Collaborative RetinaStudy Group (PACORES). Graefes Arch Clin Exp Ophthalmol 246:81\u201387","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1452_CR51","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1136\/bjo.2008.144550","volume":"92","author":"M O'Doherty","year":"2008","unstructured":"O'Doherty M, Dooley I, Hickey-Dwyer M (2008) Interventions for diabetic macular oedema: a systemic review of literature. Br J Ophthalmol 92:1581\u20131590","journal-title":"Br J Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-010-1452-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-010-1452-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-010-1452-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T15:01:03Z","timestamp":1559314863000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-010-1452-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,28]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["1452"],"URL":"https:\/\/doi.org\/10.1007\/s00417-010-1452-4","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,28]]}}}